Regarding the series of mice bearing similar size tumour volumes on the therapy starting day treated with anti-PD-1 (500/250 μg) but using a different dosing schedule (i.e., E3D vs. IMS), no significant differences were found between the E3D group (91.3 ± 53.1 days) and IMS group (85.8 ± 49.6 days) (p > 0.05 Figure 4A). Here, PDCD1 is linked to neoplasm.